SCHEMBL4494170

SCHEMBL4494170

O=C(Nc1ccnn1-c1ccccc1)c1cccc(COc2cc(Cl)ccc2Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.63
NPC1 O15118 10/20 0.63
RAB9A P51151 10/20 0.63
HPGD P15428 4/20 0.63
MAPT P10636 2/20 0.63
TDP1 Q9NUW8 1/20 0.63
ALDH1A1 P00352 5/20 0.62
TP53 P04637 2/20 0.62
THRB P10828 1/20 0.60
MRGPRX4 Q96LA9 4/20 0.58
PTGER1 P34995 2/20 0.52
GAA P10253 1/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KDM4E B2RXH2 1/20 0.47
MITF O75030 1/20 0.47
XBP1 P17861 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505850 0.77 SMN1; SMN2 (0.67) SMN1; SMN2NPC1RAB9AHPGDMAPT
Trifluoroacetic Acid SCHEMBL4511157 0.76 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AHPGDMAPT
Trifluoroacetic Acid SCHEMBL4516452 0.76 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AHPGDMAPT
SCHEMBL4509901 0.76 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9AHPGDMAPT
SCHEMBL4509295 0.75 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AHPGDMAPT
SCHEMBL4502608 0.75 MRGPRX4 (1.00) SMN1; SMN2NPC1RAB9AHPGDMAPT
Trifluoroacetic Acid SCHEMBL4502618 0.75 SMN1; SMN2 (0.62) SMN1; SMN2NPC1RAB9AHPGDMAPT
Trifluoroacetic Acid SCHEMBL4503678 0.75 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHPGDMAPT
SCHEMBL4508325 0.73 RAB9A (0.64) SMN1; SMN2NPC1RAB9AHPGDMAPT
Trifluoroacetic Acid SCHEMBL4505140 0.73 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325956-A1 Aromatic amine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325956-A1 Aromatic amine derivative and use thereof SCD, SCD5, SMS SMN1; SMN2 2075/4885NPC1 57/4885RAB9A 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.